



LAHIVE
&
COCKFIELD
L L P

COUNSELLORS AT LAW
28 STATE STREET
BOSTON, MASSACHUSETTS 02109-1784
TELEPHONE (617) 227-7400
FAX (617) 742-4214
www.lahive.com

JOHN A. LAHIVE, JR. (1928-1997)
THOMAS V. SMURZYNSKI
GIULIO A. DeCONTI, JR.
ELIZABETH A. HANLEY
AMY BAKER MANDRAGOURAS
ANTHONY A. LAURENTANO
KEVIN J. CANNING
JANE E. REMILLARD
DeANN FORAN SMITH
DEBRA J. MILASINCIC, Ph.D.
WILLIAM A. SCOFIELD, JR.
SIBLEY P. REPPERT
DAVID R. BURNS
JOHN S. CURRAN
SEAN D. DETWEILER
MEGAN E. WILLIAMS, Ph.D.
LISA DIROCCO TYNER
HATHAWAY P. RUSSELL *
MARIA LACCOTRIPE ZACHARAKIS, Ph.D.

MERIDETH C. ARNOLD
DANIELLE L. HERRITT
EUIMHOON LEE **
MANEESH GULATI
CYNTHIA M. SOROOS
PETER W. DINI, Ph.D.
MICHAEL J. BASTIAN, Ph.D.
CHRISTOPHER J. McKENNA
VINCENT P. LOCCISANO
JAMES M. McKENZIE

SENIOR COUNSEL
JAMES E. COCKFIELD

OF COUNSEL
JEREMIAH LYNCH
JEANNE M. DIGIORGIO
CYNTHIA L. KANIK, Ph.D.
JOHN D. LANZA

PATENT AGENTS *JPW*
JONATHAN M. SPARKS, Ph.D.
ANDRINA WILLIAMS ZINK
CRISTIN E. HOWLEY, Ph.D.
JILL ANN MELLO, Ph.D.
CHRISTOPHER E. DRABIK
JAMES H. VELEMA

TECHNICAL SPECIALISTS
CATHERINE M. BISHOP
JACOB G. WEINTRAUB
DEBORAH L. NAGLE, Ph.D.
ANNE JACQUELINE WIZEMAN, Ph.D.
BRIAN C. TRINQUE, Ph.D.
CHRISTOPHER R. COWLES, Ph.D.
W. ELANA WANG
CYNTHIA M. GILBERT
MEAGHAN L. RICHMOND, Ph.D.

* Admitted in TX only
** Admitted in CT only

November 9, 2004

MS Amendment
Commissioner for Patents
P.O. Box 1450
Alexandria, Virginia 22313-1450

Re: U.S. Patent Application No.: 10/699,635
For: *DEPRENYL COMPOUNDS FOR TREATMENT OF GLAUCOMA*
Inventor: William G. Tatton
Filed: October 30, 2003
Our Ref. No.: IFM-005CP4CN2

Dear Sir:

I enclose herewith for filing in the above-identified application the following:

1. Information Disclosure Statement;
2. PTO Form SB/08; and
3. A Return Postcard.

No additional costs are believed to be due in connection with the filing of this Information Disclosure Statement. However, please charge any necessary fees in connection with the enclosed statement to our Deposit Order Account No. 12-0080. For this purpose, a duplicate of this sheet is attached.

I hereby certify that this correspondence is deposited with the United States Postal Service as first class mail in an envelope addressed to:
MS Amendment, Commissioner for Patents, P.O. Box 1450,
Alexandria, Virginia 22313-1450 on:

November 9, 2004

Date

Cynthia M. Soroos
Cynthia M. Soroos, Registration No. 53,623

Respectfully submitted,
LAHIVE & COCKFIELD, LLP

Cynthia M. Soroos
Cynthia M. Soroos
Registration No. 53,623
Attorney for Applicant



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re the application of: William G. Tatton

Serial No.: 10/699,635

Filed: October 30, 2003

For: *DEPRENYL COMPOUNDS FOR TREATMENT OF GLAUCOMA*

Attorney Docket No.: IFM-005CP4CN2

Group Art Unit: 1646

Examiner: Not Yet Assigned

MS Amendment
Commissioner for Patents
P.O. Box 1450
Alexandria, Virginia 22313-1450


Certificate of First Class Mailing (37 CFR §1.8(a))

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to: MS Amendment, Commissioner for Patents, P.O. Box 1450, Alexandria, Virginia 22313-1450 on the date set forth below.

November 9, 2004

Date of Signature and of Mail Deposit

By:


Cynthia M. Soroos
Registration No. 53,623
Attorney for Applicants

INFORMATION DISCLOSURE STATEMENT


Dear Sir:

For the Examiner's convenience in reviewing this continuation application, Applicant submits a consolidated PTO Form SB/08, listing all references cited during the prosecution of the parent application. The present application is a Continuation-in-Part of U.S. Serial No. 10/211,007, filed August 2, 2002 (Atty. Docket No. IFM-CP4CN). All references listed on the enclosed PTO Form SB/08 have been previously cited by or submitted to the Office in the prior application, and, in accordance with 37 CFR §1.98(d), copies of the references are not enclosed but will be provided upon request.

This statement is not to be interpreted as a representation that the cited publications are material, that an exhaustive search has been conducted, or that no other relevant information exists. Nor shall the citation of any publication herein be construed *per se* as a representation that such publication is prior art. Moreover, Applicant understands that the Examiner will make an independent evaluation of the cited publications.

Under 37 CFR § 1.97(b)(3), no additional costs are believed to be due in connection with the filing of this disclosure. If, however, a first Office Action on the merits issues in this application bearing a mailing date prior to the date of this Information Disclosure Statement, please charge the appropriate fee as required under 37 CFR §1.17(p) to our Deposit Order Account No. 12-0080.

Respectfully submitted,
LAHIVE & COCKFIELD, LLP


Cynthia M. Soroos
Registration No. 53,623
Attorney for Applicant

28 State Street
Boston, MA 02109
(617) 227-7400

Date: November 9, 2004

EAH/CMS/les
Enclosures



PTO/SB/08a/b (08-03)

Approved for use through 07/31/2006. OMB 0651-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/B/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)				Complete if Known	
				Application Number	10/699,635
				Filing Date	October 30, 2003
				First Named Inventor	William G. Tatton
				Art Unit	1646
				Examiner Name	Not Yet Assigned
Sheet	1	of	3	Attorney Docket Number	IFM-005CP4CN2

U.S. PATENT DOCUMENTS					
Examiner Initials*	Cite No. ¹	Document Number	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number-Kind Code ² (if known)			
	A1	4,861,800	08-29-1989	Buyske	
	A2	5,242,950	09-07-1993	Fries Hastings	
	A3	5,276,057	01-04-1994	Milgram, et al.	
	A4	5,322,859	06-21-1994	Schoenwald, et al.	
	A5	5,444,095	08-22-1995	Tatton, et al.	

FOREIGN PATENT DOCUMENTS						
Examiner Initials*	Cite No. ¹	Foreign Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ⁶
		Country Code ³ -Number ⁴ -Kind Code ⁵ (if known)				
	A6	WO 85/05617 A1	12-19-1985	Chinoïn Gyogyszer		
	A7	WO 88/04552 A1	06-30-1988	Chinoïn Gyogyszer		
	A8	CA 1,329,132	12-09-1988	Somerset Pharmaceuticals		
	A9	WO 90/01928 A1	03-08-1990	Chinoïn Gyogyszer		
	A10	EP 0 473 252 A2	03-04-1992	Deprenyl Animal Health		
	A11	WO 92/17169 A1	10-15-1992	University of Toronto		
	A12	WO 92/21333 A2	12-10-1992	Pharmavene, Inc.		
	A13	WO 93/12775 A1	07-08-1993	Chinoïn Gyogyszer		
	A14	WO 95/11016 A1	04-27-1995	Teva Pharmaceutical Ind.		
	A15	WO 96/22068 A2	07-25-1996	Somerset Pharmaceuticals		
	A16	WO 96/26720 A1	09-06-1996	R.P. Scherer Ltd.		

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹ Applicant's unique citation designation number (optional). ² See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
	A17	Ariëns, E. "Stereochemistry: A Source of Problems in Medicinal Chemistry," <i>Medicinal Research Reviews</i> 6(4): 451-66 (1986)	
	A18	Birkmayer, W. et al. "Increased Life Expectancy Resulting from Addition of L-Deprenyl to Madopar® Treatment in Parkinson's Disease: A Longterm Study" <i>J. Neural Transmission</i> 64:113-127 (1985)	
	A19	Buys, Y.M. et al., "Deprenyl Rescues Retinal Ganglion Layer Cells After Optic Nerve Crush", <i>Investigative Ophthalmology & Visual Science</i> 35(4):1484, Abstract No. 1062 (1994)	

Examiner Signature		Date Considered	
-----------------------	--	--------------------	--



PTO/SB/08a/b (08-03)

Approved for use through 07/31/2006. OMB 0651-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/B/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)				Complete if Known	
				Application Number	10/699,635
				Filing Date	October 30, 2003
				First Named Inventor	William G. Tatton
				Art Unit	1646
				Examiner Name	Not Yet Assigned
Sheet	2	of	3	Attorney Docket Number	IFM-005CP4CN2

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
	B1	Greenwood, Carol E. et al. "Increased Dopamine Synthesis in Aging Substantia Nigra Neurons" <i>Neurobiology of Aging</i> 12:557-565 (1991)	
	B2	Heinonen, E.H. "Desmethylselegiline, a Metabolite of Selegiline, Is an Irreversible Inhibitor of MAO-B in Human Subjects" <i>Neurology</i> , A156, No. 19P (1993)	
	B3	Jonakait, G. Miller et al. "Development of serotonin, substance P and thyrotrophin-releasing hormone in mouse medullary raphe grown in organotypic tissue culture: developmental regulation by serotonin" <i>Brain Research</i> 473:336-343 (1988)	
	B4	Knoll, J. "The Facilitation of Dopaminergic Activity in the Aged Brain by (-)Deprenyl A Proposal for a Strategy to Improve the Quality of Life in Senescence" <i>Mechanisms of Aging and Development</i> 30:109-122 (1983)	
	B5	Magyar, K. "Behaviour of (-)-deprenyl and its analogues" <i>J. Neural Transm. Suppl.</i> 41:167-175 (1994)	
	B6	Mehra, K. et al. "Pargyline Drops in Glaucoma" <i>Arch Ophthalmol.</i> 92(6):453-454 (1974)	
	B7	The Merck Index, 10th edition, Windholz, M. (Ed.), Abstract 2893, p. 423, Abstract 6988, p. 1023, Abstract 1983; p. 282 (1983)	
	B8	Nickel, B. "Effect of selegiline and desmethyl-selegiline on cortical electric activity in rats" <i>J. Neural Transm. Suppl.</i> 32:139-144 (1990)	
	B9	Rao, T.S. "N,N-Dipropargyl-2-Phenylethylamine, A Potential Prodrug of 2-Phenylethylamine: Neurochemical and Neuropharmacological Studies in Rat" <i>Brain Research Bulletin</i> 19: 47-55 (1987)	
	B10	Riederer, P. and Youdim, M. "Monoamine Oxidase Activity and Monoamine Metabolism in Brains of Parkinsonian Patients Treated with L-Deprenyl" <i>Journal of Neurochemistry</i> 46:1359-65 (1986)	
	B11	Rinne, "Nigral degeneration in Parkinson's disease in relation to clinical features" <i>Acta Neurol Scand.</i> 84, Suppl. 136:87-90 (1991)	
	B12	Rinne, et al. "Selegiline (deprenyl) treatment and death of nigral neurons in Parkinson's disease" <i>Neurology</i> 41:859-861(1991)	
	B13	Seniuk et al. "Dose-dependent destruction of the coeruleus-cortical and nigral-striatal projections by MPTP" <i>Brain Res.</i> 527(1):7-20 (1990)	
	B14	Tatton et al. "Interactions Between MPTP-Induced and Age-Related Neuronal Death in a Murine Model of Parkinson's Disease" <i>Can. J. Neurological Sciences</i> 19:124-133 (1992)	
	B15	Tatton et al. "Different Rates of Age-Related Loss For Four Murine Monoaminergic Neuronal Populations" <i>Neurobiol. of Aging</i> 12: 543-556 (1991)	
	B16	Tatton et al. "MPTP produces reversible disappearance of tyrosine hydroxylase-containing retinal amacrine cells" <i>Brain Res.</i> 527(1): 21-31(1990)	

Examiner Signature		Date Considered	
-----------------------	--	--------------------	--



Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/B/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)				Complete if Known	
				Application Number	10/699,635
				Filing Date	October 30, 2003
				First Named Inventor	William G. Tatton
				Art Unit	1646
				Examiner Name	Not Yet Assigned
Sheet	3	of	3	Attorney Docket Number	IFM-005CP4CN2

NON PATENT LITERATURE DOCUMENTS				
Examiner Initials	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²	
	C1	Timar, Julia "Recovery of Mao-B Enzyme Activity After (-)Deprenyl (Selegiline) Pretreatment, Measured In Vivo" <i>Acta Physiologica Hungarica</i> 74(3-4):259-266 (1989)		
	C2	Torok, Tamas L. et al. "Transmitter releasing action of selegiline ((-)-deprenyl) from peripheral sympathetic nerves under different experimental conditions" <i>J. Pharm. Pharmacol.</i> 39(10):797-802 (abstract of pp. 48 of Chemical Abstracts) (1987)		
	C3	Trope, G.Z. et al. "Deprenyl Improves Visual Function in Glaucoma Patients," <i>Investigative Ophthalmology & Visual Science</i> 35(4):2178, Abstract No. 4270-40 (1994)		
	C4	Zsilla, Gabriella et al. "Neurochemical evidences for facilitation of dopaminergic function in rat brain by repeated doses of (-) deprenyl" <i>Dev. Neurosci. (Amsterdam; 17 (Regular Transm. Funct.: Basic Clin. Aspects))</i> ; Abstract of pp. 345-348; pp. 64 of Chemical Abstracts (1984)		
	C5	Zsilla, Gabriella et al. "The Effect of Repeated Doses of (-) Deprenyl On The Dynamics of Monoaminergic Transmission. Comparison With Clorgyline" <i>Pol. J. Pharmacol. Pharm.</i> 38:57-67 (1986)		
	C6	Zsilla, Gabriella et al. "(-)-Deprenyl A Selective Mao 'B' Inhibitor Increases [³ H]imipramine Binding And Decreases β-Adrenergic Receptor Function" <i>European J. of Pharmacol.</i> 89:111-117 (1983)		
	C7	Zsilla, G. and Knoll, J. "The Action of (-)Deprenyl on Monoamine Turnover Rate in Rat Brain" <i>Typical and Atypical Antidepressants: Molecular Mechanisms</i> pp. 211-217 (1982)		

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

Examiner Signature		Date Considered	
-----------------------	--	--------------------	--